High mutation rates of METTL1 and WDR4 showed significant correlations in certain tumors, and the combination of the two biomarkers could be used to construct a precise model for predicting tumor progression and response to immunotherapy in BRCA, STAD, and LGG. Here, WDR4 is linked to neoplasm.